Under special guidance from the Food and Drug Administration (FDA), the groundbreaking development comes courtesy of researchers at the Multidisciplinary Association for Psychedelic Studies (MAPS), who enrolled 90 patients suffering from severe, chronic PTSD into a randomized, blinded trial.
pocket source: https://filtermag.org/mdma-ptsd/
